Medical - Devices
Compare Stocks
4 / 10Stock Comparison
SSII vs DBVT vs ISRG vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Instruments & Supplies
Biotechnology
SSII vs DBVT vs ISRG vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $763M | $1712.35T | $161.07B | $5.90B |
| Revenue (TTM) | $42M | $0.00 | $10.58B | $1.56B |
| Net Income (TTM) | $-12M | $-168M | $2.98B | $153M |
| Gross Margin | 46.0% | — | 66.3% | 65.4% |
| Operating Margin | -19.2% | — | 30.5% | 12.3% |
| Forward P/E | — | — | 43.8x | 24.8x |
| Total Debt | $3M | $22M | $303M | $70M |
| Cash & Equiv. | $3M | $194M | $3.37B | $1.12B |
SSII vs DBVT vs ISRG vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| SS Innovations Inte… (SSII) | 100 | 1604.1 | +1504.1% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SSII vs DBVT vs ISRG vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SSII has the current edge in this matchup, primarily because of its strength in growth exposure and long-term compounding.
- Rev growth 105.7%, EPS growth 40.0%, 3Y rev CAGR 207.7%
- 162.0% 10Y total return vs ISRG's 5.5%
- 105.7% revenue growth vs DBVT's -100.0%
- Beta 0.01 vs DBVT's 1.26, lower leverage
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs SSII's -61.3%
ISRG is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
- Beta 1.02, current ratio 4.87x
- 28.2% margin vs SSII's -28.5%
- 14.8% ROA vs DBVT's -89.0%
ALKS is the clearest fit if your priority is value.
- Lower P/E (24.8x vs 43.8x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 105.7% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (24.8x vs 43.8x) | |
| Quality / Margins | 28.2% margin vs SSII's -28.5% | |
| Stability / Safety | Beta 0.01 vs DBVT's 1.26, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs SSII's -61.3% | |
| Efficiency (ROA) | 14.8% ROA vs DBVT's -89.0% |
SSII vs DBVT vs ISRG vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SSII vs DBVT vs ISRG vs ALKS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 2 of 6 categories
ALKS leads 1 • SSII leads 1 • DBVT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG and DBVT operate at a comparable scale, with $10.6B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to SSII's -28.5%. On growth, SSII holds the edge at +158.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $42M | $0 | $10.6B | $1.6B |
| EBITDAEarnings before interest/tax | -$7M | -$112M | $3.8B | $212M |
| Net IncomeAfter-tax profit | -$12M | -$168M | $3.0B | $153M |
| Free Cash FlowCash after capex | -$22M | -$151M | $2.8B | $392M |
| Gross MarginGross profit ÷ Revenue | +46.0% | — | +66.3% | +65.4% |
| Operating MarginEBIT ÷ Revenue | -19.2% | — | +30.5% | +12.3% |
| Net MarginNet income ÷ Revenue | -28.5% | — | +28.2% | +9.8% |
| FCF MarginFCF ÷ Revenue | -52.3% | — | +26.8% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +158.4% | — | +23.0% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +69.0% | +91.5% | +18.8% | -4.1% |
Valuation Metrics
ALKS leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ALKS trades at a 57% valuation discount to ISRG's 57.6x P/E. On an enterprise value basis, ALKS's 17.3x EV/EBITDA is more attractive than ISRG's 43.6x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $763M | $1712.35T | $161.1B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $763M | $1712.35T | $158.0B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | -65.50x | -0.76x | 57.62x | 24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.84x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | — |
| EV / EBITDAEnterprise value multiple | — | — | 43.62x | 17.25x |
| Price / SalesMarket cap ÷ Revenue | 17.96x | — | 16.00x | 4.00x |
| Price / BookPrice ÷ Book value/share | 20.43x | 0.66x | 9.17x | 3.28x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | 12.28x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-130 for DBVT. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -30.2% | -130.2% | +16.9% | +8.8% |
| ROA (TTM)Return on assets | -17.5% | -89.0% | +14.8% | +5.4% |
| ROICReturn on invested capital | -17.7% | — | +15.0% | +18.9% |
| ROCEReturn on capital employed | -23.6% | -145.7% | +16.5% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.08x | 0.13x | 0.02x | 0.04x |
| Net DebtTotal debt minus cash | -$289,540 | -$172M | -$3.1B | -$1.0B |
| Cash & Equiv.Liquid assets | $3M | $194M | $3.4B | $1.1B |
| Total DebtShort + long-term debt | $3M | $22M | $303M | $70M |
| Interest CoverageEBIT ÷ Interest expense | -7.35x | -189.82x | — | 32.30x |
Total Returns (Dividends Reinvested)
SSII leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SSII five years ago would be worth $38,155 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs SSII's -61.3%. The 3-year compound annual growth rate (CAGR) favors SSII at 82.1% vs ALKS's 4.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -30.4% | +4.9% | -19.3% | +25.3% |
| 1-Year ReturnPast 12 months | -61.3% | +110.4% | -15.4% | +16.5% |
| 3-Year ReturnCumulative with dividends | +503.7% | +19.7% | +49.6% | +14.5% |
| 5-Year ReturnCumulative with dividends | +281.6% | -69.1% | +58.7% | +60.9% |
| 10-Year ReturnCumulative with dividends | +162.0% | -87.0% | +554.2% | -11.0% |
| CAGR (3Y)Annualised 3-year return | +82.1% | +6.2% | +14.4% | +4.6% |
Risk & Volatility
Evenly matched — SSII and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
SSII is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs SSII's 33.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.01x | 1.26x | 1.02x | 1.06x |
| 52-Week HighHighest price in past year | $11.87 | $26.18 | $603.88 | $36.60 |
| 52-Week LowLowest price in past year | $3.02 | $7.53 | $427.84 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +33.1% | +76.3% | +75.1% | +96.7% |
| RSI (14)Momentum oscillator 0–100 | 39.1 | 48.1 | 42.4 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 54K | 252K | 1.8M | 2.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ISRG as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 24.3% for ALKS (target: $44).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $622.60 | $44.00 |
| # AnalystsCovering analysts | — | 15 | 55 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +1.4% | +0.5% |
ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ALKS leads in 1 (Valuation Metrics). 1 tied.
SSII vs DBVT vs ISRG vs ALKS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SSII or DBVT or ISRG or ALKS a better buy right now?
For growth investors, SS Innovations International, Inc.
(SSII) is the stronger pick with 105. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SSII or DBVT or ISRG or ALKS?
On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.
8x versus Intuitive Surgical, Inc. at 57. 6x.
03Which is the better long-term investment — SSII or DBVT or ISRG or ALKS?
Over the past 5 years, SS Innovations International, Inc.
(SSII) delivered a total return of +281. 6%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SSII or DBVT or ISRG or ALKS?
By beta (market sensitivity over 5 years), SS Innovations International, Inc.
(SSII) is the lower-risk stock at 0. 01β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 8633% more volatile than SSII relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — SSII or DBVT or ISRG or ALKS?
By revenue growth (latest reported year), SS Innovations International, Inc.
(SSII) is pulling ahead at 105. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: SS Innovations International, Inc. grew EPS 40. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, SSII leads at 207. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SSII or DBVT or ISRG or ALKS?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -28. 5% for SS Innovations International, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -19. 2% for SSII. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SSII or DBVT or ISRG or ALKS more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 131.
8% to $46. 33.
08Which pays a better dividend — SSII or DBVT or ISRG or ALKS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SSII or DBVT or ISRG or ALKS better for a retirement portfolio?
For long-horizon retirement investors, SS Innovations International, Inc.
(SSII) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), +162. 0% 10Y return). Both have compounded well over 10 years (SSII: +162. 0%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SSII and DBVT and ISRG and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SSII is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ISRG is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.